

Global

Globally, in Q1'17 VC-backed companies raised **\$26.8B** across **2,716** deals



Corporate VC participation as a % of total deal count reaches high in Q1'17 on a quarterly basis



Globally, the median series B funding hits **\$14M** in size in Q1'17 rising from **\$12M** in 2016



Globally, the size of median series C financings slid from **\$23M** in 2016 to **\$22M** in Q1'17



Globally, pharma and biotech saw **\$3.9B** invested already in 2017



Americas



In Q1'17 VC-backed companies in the Americas raised **\$17.8B** across **1,878** deals

Canada sees a down quarter of **\$257M** after a record year in 2016



Size of Series D median financings in the Americas returns to high of **\$30M**



Angel and seed deals continue to dominate deal share in the Americas at **54%**



US

In Q1'17 US VC-backed companies raised **\$17.3B** across **1,809** deals



497 first-time financings were logged in the US during Q1'17 with a total of **\$1.6B** invested



Median financing sizes plateau or increase only slightly in Q1'17 in the US



Pharma and Biotech account for **\$3.1B** of the investment in the US in Q1'17



Europe

In Q1'17 European VC-backed companies raised **\$3.4B** across **565** deals



Investment in software experiences a surge in Europe to **48%** of Q1'17 deal volume



Corporate VC participation spikes in Q1'17 to **21.8%** of total deal activity



London bounces back in amount of capital invested from **\$451M** in Q4'16 to **\$653M** in Q1'17



Asia

In Q1'17 VC-backed companies in Asia raised **\$5.6B** across **258** deals



Asia sees rally in median financing sizes across all stages in Q1'17



3 of the top **10** financings in Asia in Q1'17 are based in Shanghai



Corporate VC participation remains steady in Asia in Q1'17 at **19.8%** of total deal count

